News
-
-
-
-
PRESS RELEASE
NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials
NanoViricides, Inc. announces successful safety and tolerability results of broad-spectrum antiviral drug NV-387 in juvenile animal model study, paving the way for pediatric clinical trials -
-
PRESS RELEASE
Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides
NanoViricides reports progress in Phase IIA Ebola Treatment Clinical Trial for NV-387 Oral Gummies, evaluating dosage regimens and efficacy against Ebola Bundibugyo virus, with safety and tolerability focus -
-
PRESS RELEASE
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
NanoViricides, Inc. provides details on Phase II Clinical Trial of NV-387 Oral Gummies for treating Bundibugyo Ebolavirus (BDBV) outbreak in DRC. Trial targets optimal dosing regimen and safety signals for Ebola Virus Disease patients -
-
PRESS RELEASE
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
NanoViricides, Inc. reports filing the Annual Report on Form 10-K with SEC showcasing achievements including Phase II trials for NV-387, an antiviral drug for Mpox and Ebola. Financials and milestones are detailed
